Precision Oncology Referrals: A Guide for Community Doctors

Precision Oncology: What Community Doctors Should Know Before Referring Patients

Introduction

Cancer treatment in India is changing shape. A diagnosis of lung cancer or breast cancer no longer automatically leads to one standard chemotherapy protocol. Increasingly, treatment decisions depend on the molecular fingerprint of the tumour itself, an approach broadly known as precision oncology. For community doctors and general physicians, who are frequently the first point of contact when a patient receives a cancer diagnosis or begins experiencing worrying symptoms, understanding the basics of precision oncology has become essential. It shapes how quickly a patient is referred, which tests are requested, and ultimately, how much benefit a patient can draw from newer targeted treatments.

This is not a call for general physicians to become oncologists. Rather, it is about recognising the clinical situations where a referral for biomarker testing and specialist molecular oncology input can materially change a patient's treatment pathway. A timely, well-informed referral can mean the difference between a patient receiving a therapy matched to their tumour biology and a patient going through months of treatment that was never likely to work for them. Given India's growing cancer burden, projected to cross over 15 lakh new cases annually according to ICMR's National Cancer Registry Programme estimates, this knowledge gap between primary care and specialist oncology deserves closer attention.

Understanding Precision Oncology: The Basic Concept

Precision oncology, sometimes called personalised or molecular oncology, is built on a simple premise. Two patients with the same type of cancer, say non-small cell lung cancer, may have tumours driven by entirely different genetic alterations. One tumour might carry an EGFR mutation, another an ALK rearrangement, and a third might have no identifiable driver alteration at all. Traditional chemotherapy treats all three patients similarly. Precision oncology, by contrast, uses biomarker testing, which may involve next-generation sequencing (NGS), immunohistochemistry, or targeted molecular panels, to identify these differences and match patients to therapies designed specifically for their tumour's biology.

It is worth being candid about the limits of this approach, since overstating its reach does a disservice to patients and doctors alike. Precision oncology does not benefit everyone equally. International data, including a widely cited 2021 study in Frontiers in Oncology, found that among 1,000 patients who underwent comprehensive genomic profiling, only around 1.4 percent ultimately received a treatment benefit that could be directly attributed to the test result. Later analyses have placed the proportion of patients with a truly actionable and beneficial finding at a modest fraction of those tested, even though many more show some detectable alteration. This does not mean the approach lacks value. It means that community doctors should understand precision oncology as a tool that helps a defined subset of patients meaningfully, not as a universal solution that should be pursued reflexively in every cancer case.

In India, the growing molecular oncology ecosystem is being supported by both government and private sector initiatives. The DHR-ICMR Advanced Molecular Oncology Diagnostic Services scheme, known as DIAMOnDS, has established zonal oncopathology laboratories across government medical colleges to provide free or subsidised molecular testing for lung and breast cancer patients, particularly benefiting those who cannot afford private genomic panels. Alongside this, several private diagnostic and pharmaceutical partnerships have begun offering targeted biomarker testing, such as IDH1 and IDH2 testing for acute myeloid leukaemia and cholangiocarcinoma, at no cost in government hospitals. Community doctors practising in tier two and tier three cities should be aware that these pathways exist, since patients in these regions often assume that molecular testing is only available in metro centres.

When Should a Community Doctor Consider Referral

Recognising the right moment to refer a patient for precision oncology evaluation is arguably more valuable to a general physician than memorising the details of specific biomarkers. Certain clinical scenarios should prompt consideration of a referral to a medical oncologist or a centre with molecular tumour board capability.

Patients presenting with advanced or metastatic solid tumours are the strongest candidates. This includes non-small cell lung cancer, particularly in patients who have never smoked or have a light smoking history, metastatic colorectal cancer, hormone receptor and HER2 status assessment in breast cancer, and certain gynaecological and gastrointestinal malignancies where targetable alterations are increasingly well characterised. Age is another useful signal. Cancer diagnosed in a patient under 50, especially without the usual risk factor profile, raises the possibility of a hereditary cancer syndrome and warrants consideration of genetic counselling alongside tumour biomarker testing.

Family history deserves particular attention in Indian primary care settings, where multigenerational household structures often mean the general physician has visibility into extended family patterns that a hospital-based specialist may not immediately have. Multiple first-degree relatives with breast, ovarian, colorectal, or pancreatic cancer, or any relative diagnosed with cancer before the age of 45, are patterns that should prompt a conversation about referral for genetic risk assessment, independent of the patient's own diagnosis.

It is equally important for community doctors to recognise when precision oncology referral is unlikely to add value in the immediate term. Early stage, surgically resectable cancers with well-established standard of care protocols, patients with significant comorbidities that would preclude targeted therapy regardless of biomarker findings, and patients who have expressed a clear preference for supportive or palliative care are situations where the urgency of a molecular workup referral is lower. Setting realistic expectations here protects patients from unnecessary cost and anxiety.

What the Referral and Testing Process Typically Involves

Once a decision to refer has been made, community doctors are often asked by patients and families to explain what comes next. Having a basic working knowledge of this pathway builds trust and helps manage expectations.

The process generally begins with tissue or liquid biopsy sample collection, often coordinated by the receiving oncology centre rather than the referring physician. Adequate tissue quantity and quality matter considerably here, and this is one reason why early referral, before a patient has undergone multiple prior procedures that may deplete available tissue, is preferable. The sample is then sent for molecular analysis, which may range from a focused panel testing a handful of common alterations to comprehensive genomic profiling covering hundreds of genes, depending on the cancer type and clinical question.

Turnaround time for results varies, typically ranging from one to three weeks depending on the laboratory and test complexity, which is a detail worth communicating to patients so they understand that a delay in results is not the same as a delay in care. Results are usually reviewed by a molecular tumour board, a multidisciplinary group of medical oncologists, pathologists, and molecular biologists, who interpret findings in the context of the individual patient before recommending a treatment pathway. This is a meaningful distinction from ordering a routine laboratory test, where the referring doctor might interpret results independently. Precision oncology results are rarely straightforward, and interpretation without specialist input can lead to inappropriate treatment decisions.

Cost remains a genuine barrier for many Indian families, and community doctors are often the ones fielding the first anxious question about affordability. Comprehensive genomic panels from private laboratories can range from tens of thousands to over a lakh of rupees, though targeted, single-gene tests are considerably less expensive. Where financial constraints exist, doctors should be aware of DIAMOnDS centres, applicable coverage under Ayushman Bharat for certain cancer treatments, and patient assistance programmes run by pharmaceutical companies and diagnostic laboratories, several of which have expanded in recent years to cover specific biomarker panels for lung, breast, and haematological cancers at government facilities.

Communicating Precision Oncology to Patients

Indian patients and families frequently arrive at a cancer diagnosis with significant fear, and the introduction of terms like genomic testing or targeted therapy can either provide reassurance or add to confusion, depending on how the conversation is framed. Community doctors are often best placed to have this first conversation, well before the oncology consultation, simply because of the existing relationship and trust.

A few principles help here. Avoid presenting biomarker testing as a guarantee of a better outcome, since this creates expectations that may not be met. Explain, in plain language, that the test looks for specific characteristics of the tumour that may help the oncology team choose the most suitable treatment, and that not every patient will have a result that changes their treatment plan. Where the cost of testing is a barrier, raise this openly rather than assuming the family cannot afford it, since eligibility for subsidised or free testing schemes is not always obvious from a patient's outward circumstances. Finally, resist the temptation to explain specific biomarker results in detail if you have not had specialist training in interpreting them. Molecular oncology terminology is nuanced, and an incomplete explanation from a well-meaning referring doctor can sometimes create more confusion than clarity.

Building Stronger Referral Pathways

The gap between primary care and specialist oncology in India is not simply a matter of individual doctor awareness. It reflects broader systemic challenges, including uneven distribution of molecular tumour board access, limited standardisation of referral protocols between community clinics and cancer centres, and inconsistent communication of test results and their clinical implications back to referring physicians. These structural issues will take time and coordinated effort across professional associations, hospitals, and diagnostic networks to resolve.

In the meantime, individual doctors can strengthen their own referral pathways by building direct relationships with oncology centres in their region, staying updated through continuing medical education on which cancers currently have the strongest evidence base for biomarker-driven treatment, and participating in professional forums where oncologists and general physicians can exchange practical experience. Platforms built for doctor-to-doctor communication and professional knowledge sharing have a genuine role to play here, giving community physicians a space to ask oncology colleagues direct questions, follow updates on evolving standards of care, and stay connected with the broader medical community as precision oncology practices continue to evolve across the country.

Conclusion

Precision oncology is reshaping cancer care in India, but its benefit depends heavily on timely and well-judged referral decisions made at the primary care level. Community doctors do not need to master the technical details of genomic sequencing to play a meaningful role. What matters most is recognising the clinical situations that warrant referral, understanding realistically what biomarker testing can and cannot offer, being aware of the financial support pathways available to patients, and communicating with patients honestly about what lies ahead. As India's molecular oncology infrastructure continues to expand through both government initiatives and private partnerships, the community doctor's judgement at that first point of contact remains one of the most consequential steps in a patient's cancer journey.

Frequently Asked Questions

Q1: What is precision oncology in simple terms?

Precision oncology is an approach to cancer treatment that uses information about the specific genetic and molecular features of a patient's tumour to guide treatment choices, rather than relying only on the cancer's site and stage.

Q2: Which patients should a community doctor consider referring for biomarker testing?

Patients with advanced or metastatic solid tumours such as lung, breast, colorectal, and certain gastrointestinal or gynaecological cancers are generally the strongest candidates, along with younger patients or those with a strong family history suggestive of a hereditary cancer syndrome.

Q3: Is precision oncology testing affordable in India?

Costs vary widely depending on the type and breadth of the test. Government initiatives such as the DHR-ICMR DIAMOnDS centres and select industry patient assistance programmes have started offering selected biomarker tests free of cost or at subsidised rates in government hospitals, though wider access outside these programmes remains limited.

Q4: Does biomarker testing guarantee a targeted therapy will work?

No. Biomarker testing identifies whether a targetable alteration is present, but only a proportion of tested patients will have an actionable finding, and response to targeted therapy still depends on multiple clinical factors including overall health status and disease stage.

Q5: Should a community doctor order genomic testing directly or refer to an oncologist first?

In most cases, referral to a medical oncologist or a centre with a molecular tumour board is preferable, since test selection, tissue adequacy, interpretation, and treatment decisions require specialised expertise that extends beyond ordering the test itself.

#PrecisionOncology #CancerCareCollaboration